SCHEMBL10074498

SCHEMBL10074498

CCc1nnnnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14050809 0.76
SCHEMBL2614743 0.72 HRH4 (0.33)
SCHEMBL16625933 0.69
SCHEMBL21257038 0.67
Hydrochloric Acid SCHEMBL28946231 0.67 HRH4 (0.31)
SCHEMBL8755276 0.62 HSP90AA1 (0.31)
SCHEMBL8755416 0.62 HSP90AA1 (0.31)
SCHEMBL3875958 0.60
SCHEMBL2623099 0.60 HRH4 (0.50)
SCHEMBL10353126 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838897-A2 (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY Shenzhen TargetRx, Inc. (CN) 2021-06-23 EP disclosed
EP-3553056-B1 (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY SHENZHEN TARGETRX INC (CN) 2021-02-17 EP disclosed
EP-3553056-A1 (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-10-16 EP disclosed
US-20120328546-A1 Paxillin Stimulating Compositions and Cosmetic Uses Thereof AVON PRODUCTS, INC. (US) 2012-12-27 US disclosed
US-8168212-B2 Topical compositions comprising non-proteogenic amino acids and methods of treating skin AVON PRODUCTS, INC (US) 2012-05-01 US disclosed
US-20100311748-A1 HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS ASTRAZENECA AB (SE) 2010-12-09 US disclosed
US-20100261769-A1 Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin AVON PRODUCTS, INC. (US) 2010-10-14 US disclosed